Subscribe or Manage Preferences
Urology Practice Management - August 2015, Vol 4, No 4 - Prostate Cancer
Wayne Kuznar

Enzalutamide (Xtandi) outperformed bicalutamide (Casodex) in 2 separate phase 2 clinical trials of men with prostate cancer, according to data presented at the 2015 American Urological Association annual meeting.

Enzalutamide was associated with longer progression-free survival (PFS) and a greater benefit in health-related quality of life compared with bicalutamide in men with metastatic castration-resistant prostate cancer (CRPC) in the TERRAIN trial, said Arnauld A. Villers, MD, PhD, Professor of Urology, University of Lille, France.

All 375 patients had asymptomatic or mildly symptomatic metastatic CRPC that had progressed after treatment with a luteinizing hormone-releasing hormone analog or after surgical castration. The patients were randomized to enzalutamide 160 mg daily or to bicalutamide 50 mg daily.

To be eligible, patients had to have ≥2 bone lesions or soft-tissue disease, progressive disease, ongoing gonadotropin-releasing hormone analog therapy or surgical castration, and a life expectancy of ≥1 years.

The median PFS, the primary end point, was 15.7 months in the enzalutamide arm compared with 5.8 months in the bicalutamide arm, corresponding to a hazard ratio of 0.44 (P <.001). “The separation between the 2 curves was seen early, at 3 months,” said Dr Villers.

At week 13, 82% of patients receiving enzalutamide had a prostate-specific antigen (PSA) response (≥50% reduction) versus 21% of patients in the bicalutamide arm, and 56% of patients had a PSA reduction of ≥90% versus 5% of patients in the bicalutamide arm. “Half of the patients in the enzalutamide arm reached a ≥90% decrease in PSA by month 6,” Dr Villers said.

Enzalutamide was also significantly superior to bicalutamide in 5 of 7 quality-of-life domains. The quality of life was maintained for a significantly longer time in the enzalutamide group, said Dr Villers.

Exposure to enzalutamide was double that seen with bicalutamide, a median of 11.7 months versus 5.8 months, respectively. The rates of serious adverse events were 31% in the enzalutamide arm and 23% in the bicalutamide arm. There were 3 seizures overall—2 in the enzalutamide arm and 1 in the bicalu­tamide arm.

In a second randomized, phase 2 study, known as STRIVE, enzalutamide was superior to bicalutamide as an add-on to androgen-deprivation therapy in men with nonmetastatic CRPC or metastatic CRPC, said Celestia S. Higano, MD, Professor of Medicine and Urology, University of Washington, Seattle.

In STRIVE, 396 patients were randomized to enzalutamide or bica­lutamide at the same dosages that were used in TERRAIN.

The median PFS was 19.4 months in men receiving enzalutamide versus 5.7 months in those receiving bicalutamide (P <.001). The time to PSA progression also favored enzalutamide.

In the enzalutamide arm, 81% of the patients had a ≥50% decline in PSA level compared with only 31% in the bicalutamide arm, and 65% in the enzalutamide arm had a ≥90% decrease in PSA levels compared with 9% in the bicalutamide arm.

“The enzalutamide arm is superior to the bicalutamide arm…on both the primary and key secondary end points,” said Dr Higano.

The median durations of treatment were 14.7 months in the enzalutamide arm versus 8.4 months in the bicalutamide arm.

Related Items
Treat Your Patients as Customers by Meeting Their Expectations
Wayne Kuznar
Rheumatology Practice Management April 2018 Vol 6 No 2 published on April 16, 2018 in NORM Conference News
2017 HIPAA Updates and the Office for Civil Rights Audits
Wayne Kuznar
Rheumatology Practice Management October 2017 Vol 5 No 5 published on October 20, 2017 in NORM News
Abiraterone Is Game-Changer in the Frontline Treatment of Advanced Prostate Cancer
Wayne Kuznar
Urology Practice Management - Web Exclusives published on July 21, 2017 in Prostate Cancer
Adding Antiandrogen Therapy to Radiation Improves Survival in Recurrent Prostate Cancer—A New Standard of Care?
Jessica Miller
Urology Practice Management - Web Exclusives published on May 15, 2017 in Prostate Cancer
Rise in Metastatic Prostate Cancer Has Screening, Treatment Implications
Charles Bankhead
Urology Practice Management - December 2016, Vol 5, No 6 published on December 7, 2016 in Prostate Cancer
Promising Antitumor Activity of ODM-201 in Metastatic Prostate Cancer
Wayne Kuznar
Urology Practice Management - December 2016, Vol 5, No 6 published on December 7, 2016 in Prostate Cancer
Is the Glass Half Empty or Half Full? First Study Compares Robotic-Assisted Surgery and Open Radical Prostatectomy
Alice Goodman
Urology Practice Management - December 2016, Vol 5, No 6 published on December 7, 2016 in Prostate Cancer
IsoPSA, a New Biomarker Test, Differentiates High- and Low-Grade Prostate Cancer, Improves Diagnostic Accuracy
Wayne Kuznar
Urology Practice Management - October 2016, Vol 5, No 5 published on October 10, 2016 in Prostate Cancer
Shorter Hypofractionated Therapy New Standard for Prostate Cancer
Phoebe Starr
Urology Practice Management - October 2016, Vol 5, No 5 published on October 10, 2016 in Prostate Cancer
Atezolizumab Could Be Start of “Seismic Shift” in Metastatic Bladder Cancer Therapy
Wayne Kuznar
Urology Practice Management - August 2016, Vol 5, No 4 published on August 15, 2016 in Bladder Cancer
Last modified: August 17, 2015
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management

Search